EWING SARCOMA

This study is testing a personalized peptide vaccine for children and young adults (up to age 30) with metastatic fusion-driven sarcomas (Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma) who have completed standard treatment. The vaccine is custom-made for each patient based on…

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This early-phase trial is testing a drug called xaluritamig in about 50 people with Ewing sarcoma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This study tests a new treatment for people with sarcoma that has come back or is advanced. It combines low-dose chemotherapy with special immune cells (CAR T cells) and vaccines to fight the cancer. The goal is to see if this approach is safe and helps shrink tumors or improve s…

This study is for people with bone sarcomas who have completed their first round of treatment. It tests whether taking regorafenib for up to 12 months can help prevent the cancer from coming back, compared to standard monitoring. About 168 participants will be randomly assigned t…

This early-phase trial tests a new treatment made from a patient's own immune cells, engineered to better recognize and attack certain childhood solid tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor). The study enrolls up to 18 children and young adults wh…

This early-stage study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. The treatment combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation and chemotherapy to see…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have returned or are hard to treat. The transplant uses a half-matched donor and removes certain immune cells to lower the risk of graft-versus-host disease. A drug ca…

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About …

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This early-phase trial tests the safety and best dose of cabozantinib combined with high-dose ifosfamide in 30 children and adults with sarcomas (like Ewing sarcoma or osteosarcoma) that have returned or not responded to standard chemotherapy. The goal is to find a dose that cont…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This early-stage trial tests a new treatment called B7-H3CART, which uses a patient's own immune cells modified to target a protein (B7-H3) found on certain solid tumors. It includes up to 41 children and young adults with relapsed neuroblastoma, sarcoma, or osteosarcoma who have…

This study tests whether giving targeted radiation to cancer that has spread (metastases) can help children and young adults with sarcoma live longer. About 70 participants under 39 with newly diagnosed soft tissue or bone sarcoma will receive consolidative radiation therapy. Res…

This early-phase trial tests whether specially grown immune cells (T cells) that recognize multiple tumor proteins can be safely given to children with high-risk solid tumors like neuroblastoma or sarcoma. The cells come from a healthy donor and are matched to the patient's immun…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This study tests a drug called lurbinectedin in people aged 10 and older whose solid tumors (like Ewing sarcoma) have returned after standard treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic c…

This study tests whether adding specially trained immune cells (NK cells) to standard chemotherapy can help children and young adults with sarcoma that has returned or not responded to prior treatments. About 50 participants aged 2 to 40 with certain types of sarcoma will receive…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests whether adding eflornithine (DFMO) to standard chemotherapy can help teens and young adults with Ewing sarcoma or osteosarcoma live longer without their cancer coming back. About 406 participants will join one of five groups based on their cancer type and stage. …

This study tests a new way of giving radiation therapy for Ewing sarcoma, a rare bone and soft tissue cancer. The radiation dose is tailored to each patient's tumor size and biology, with higher doses given over a shorter time. The goal is to reduce the chance of the cancer retur…

This early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…

This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Abou…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 60 participants w…

This study looks at two lab tests (RT-qPCR and ddPCR) to find leftover cancer cells in ovarian or testicular tissue that was frozen to preserve fertility in children with neuroblastoma or Ewing sarcoma. The goal is to see which test is better at detecting tiny amounts of cancer, …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study looks at how closely bone cancer patients follow a personalized home exercise program in the first six months after lower leg surgery. Researchers will track daily exercise logs and explore what factors help or hinder adherence. The goal is to improve rehabilitation su…